Peptide Therapy for Anti-Aging: What the Research Actually Shows

Peptides are having a moment. In longevity clinics and biohacker circles alike, conversations about BPC-157, sermorelin, CJC-1295/ipamorelin, and TB-500 are everywhere. The claims range from plausible to fantastical: faster recovery, better sleep, improved body composition, reduced inflammation, cellular repair, and yes — anti-aging effects.

But what does the evidence actually say? This is a field where enthusiasm often outruns data. Here's a rigorous look at peptide therapy for anti-aging — what's well-supported, what's promising but limited, and what's mostly noise.

What Are Peptides, Exactly?

Peptides are short chains of amino acids — essentially small proteins. The human body produces thousands of naturally occurring peptides that act as signaling molecules: hormones, neurotransmitters, growth factors. Many pharmaceutical drugs are synthetic peptides designed to mimic or modulate these natural signals.

The peptides used in longevity and anti-aging medicine fall into several functional categories:

1. Growth hormone secretagogues (GHS): Stimulate the pituitary to release more growth hormone (GH). Examples: sermorelin, CJC-1295, ipamorelin, GHRP-2, GHRP-6.
2. Tissue repair peptides: Promote healing and reduce inflammation. Examples: BPC-157, TB-500 (thymosin beta-4).
3. Metabolic peptides: Improve insulin sensitivity and body composition. Some overlap with GHS category.
4. Cognitive peptides: Neuroprotective effects, studied in neurodegeneration. Examples: Selank, Semax (primarily Russian research).

Growth Hormone Secretagogues: The Most Studied Category

As we age, growth hormone secretion declines dramatically — by roughly 14% per decade from peak levels. Lower GH is associated with increased visceral fat, reduced lean mass, decreased bone density, impaired immune function, poorer sleep quality, and reduced recovery from injury. Much of what we colloquially call "aging" mirrors GH-deficient states.

Growth hormone secretagogues address this by stimulating the pituitary's natural GH release — rather than replacing GH directly (which carries more significant side effect risks and is tightly regulated).

### Sermorelin

Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It's been FDA-approved (though currently off-market as a brand-name product) and has the most robust human clinical data of any GHS.

What the research shows: - Studies in older adults with GH deficiency show improved lean mass, reduced fat mass, improved sleep architecture (GH is released primarily during slow-wave sleep), better skin texture, and improved energy - A 2010 study in *Clinical Interventions in Aging* showed sermorelin improved GH/IGF-1 levels and body composition in GH-deficient adults with a favorable safety profile - Unlike exogenous GH administration, sermorelin preserves the normal pulsatile pattern of GH release, which appears important for metabolic effects

Practical considerations: Sermorelin is typically administered as a nightly subcutaneous injection (0.2-0.3mg). Effects develop over 3-6 months. IGF-1 monitoring is recommended to assess response and avoid supraphysiologic levels.

[Learn more about sermorelin therapy →](/sermorelin-therapy)

### CJC-1295 / Ipamorelin

CJC-1295 is a modified GHRH analog with a longer half-life than sermorelin. Ipamorelin is a ghrelin mimetic that stimulates GH release via a different receptor. They're frequently combined because they act synergistically on complementary pathways.

What the research shows: - CJC-1295 DAC (with drug affinity complex) extends half-life dramatically, allowing once-weekly dosing in some protocols - A 2006 *Journal of Clinical Endocrinology & Metabolism* study showed CJC-1295 produced dose-dependent increases in GH and IGF-1 with a favorable safety profile in healthy adults - Ipamorelin has a clean GH release profile with minimal cortisol or prolactin stimulation — an advantage over older GHRPs - The combination produces more robust GH pulses than either agent alone

BPC-157: The Healing Peptide

Body Protection Compound 157 (BPC-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It's one of the most discussed compounds in recovery and anti-aging medicine — and one of the most complicated to evaluate.

What the research shows (primarily animal models): - Remarkable wound healing and tissue repair effects in rodent studies across virtually every tissue type tested: tendon, muscle, bone, nerve, gut lining, skin - Anti-inflammatory effects via modulation of nitric oxide pathways - Neuroprotective effects in brain injury models - Gut healing effects that are particularly well-documented

The evidence gap: The vast majority of BPC-157 research is in animal models. Human clinical trials are very limited. A few small human studies for inflammatory bowel disease exist, showing promising safety data. But the translation from rat models to human biology is not proven.

The practical reality: Despite limited human data, BPC-157 has been used extensively by athletes and longevity-focused individuals who report meaningful improvements in injury recovery and joint health. The safety profile appears favorable based on available data. The FDA has recently taken action against certain peptide vendors and 503A compounders who market BPC-157 for human use — regulatory status is evolving.

TB-500 (Thymosin Beta-4 Fragment)

TB-500 is a synthetic fragment of the thymosin beta-4 protein, which plays roles in actin regulation, cell migration, wound healing, and inflammation. It's often paired with BPC-157 in recovery protocols.

What the research shows: - Thymosin beta-4 (the full protein) has well-documented roles in cardiac repair and wound healing in multiple animal studies - TB-500 specifically has less research than the full protein - A small human cardiac trial showed thymosin beta-4 was safe and potentially beneficial in acute MI patients - Athletic recovery reports are extensive but anecdotal

Assessment: Interesting mechanism, limited human data, reasonable safety profile. More speculative than GH secretagogues.

NAD+ Precursors as Peptide Adjuncts

While not peptides per se, NAD+ precursors (NMN, NR) are often combined with peptide protocols in longevity medicine. NAD+ is a critical coenzyme that declines with age, and its restoration has been shown to improve mitochondrial function, DNA repair mechanisms, and insulin sensitivity.

[Learn about NAD+ at Marrow →](/nad-plus-online)

What the Evidence Actually Supports

Being honest about the evidence hierarchy:

Well-supported by human clinical data: - Sermorelin for GH deficiency: solid evidence for body composition, sleep, and vitality improvements - CJC-1295 for GH pulsatility: good Phase I/II data in healthy adults

Promising but limited human data: - BPC-157: extensive animal data, minimal human trials; used widely with apparent safety - TB-500: mechanistically interesting, more limited data than BPC-157

Primarily theoretical/anecdotal: - Many peptides marketed aggressively online with no credible human studies

Working With a Qualified Provider

The regulatory environment for peptides is complex and evolving. Some peptides are compounded legally through FDA-registered pharmacies; others are available only as research chemicals through unregulated sources. The difference in quality control, purity, and safety is enormous.

Working with a licensed physician who monitors bloodwork (particularly IGF-1 for GH secretagogues) is essential for any peptide protocol. At Marrow, we offer sermorelin as part of our longevity track with appropriate monitoring. [Start a consultation →](/start)